Previous 10 | Next 10 |
Gainers: IVERIC bio (NASDAQ:ISEE) +56%, Endo (NASDAQ:ENDP) +46%, NGM Biopharmaceuticals (NASDAQ:NGM) +16%, Arbutus Biopharma (NASDAQ:ABUS) +15%, CareMax (NASDAQ:CMAX) +11%. Losers: Apellis Pharmaceuticals (NASDAQ:APLS) -50%, Mersana Therapeuti...
IVERIC bio (NASDAQ:ISEE) +65% Apellis' mixed eye-drug data turns out to be 'positive' for Iveric Bio Vince Holding (NYSE:VNCE) +22% on Q2 earnings. Affirm Holdings (NASDAQ:AFRM) +21% on Q4 earnings. Endo International (NASDAQ:ENDP) +18% settles New York state opi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re back at it again with one last day of trading this week and we’re kicking it off with a dive into Friday’s biggest pre-market stock movers. Source: Shutterstock The...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Image source: The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q2 2021 Earnings Call Aug 05, 2021 , 8:45 a.m. ET Operator Continue reading For further details see: Arbutus Biopharma (ABUS) Q2 2021 Earnings Call Transcript
Arbutus Biopharma Corporation (ABUS) Q2 2021 Earnings Conference Call August 05, 2021 08:15 AM ET Company Participants Pam Murphy - IR Bill Collier - President, CEO Dave Hastings - CFO Gaston Picchio - CDO Mike Sofia - CSO Conference Call Participants Roy Buchanan - JMP Securities Keay Nakae ...
Arbutus Biopharma (NASDAQ:ABUS) shares rise more than 3% premarket after the company reported second-quarter revenue that beat Wall Street estimates, and provided a cash position update. The company's quarterly revenue increased 54% to $2.33M, beating analysts' estimate by $0.23M. A...
New data on AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, highlighted in four abstracts at the EASL International Liver Congress™ ; all AB-729 abstracts selected for best of ILC™ Announced two additional proof-of-concept clinical coll...
WARMINSTER, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...